- Policy
- Competition intensifies in 3-combo drug mkt for COPD·asthma
- by Lee, Tak-Sun Feb 23, 2024 05:48am
- Competition in the market for three-drug combinations used to treat COPD (chronic obstructive pulmonary disease) and asthma has become somewhat complicated. Kolon Pharma’s Trimbow, which was introduced in January, triggered the competition, and GSK’s Trelegy Ellipta, which had enjoyed its sole lead in the market till then, strengthened
- Policy
- Gov't 'Too soon to price immune-oncology drugs by indication
- by Lee, Jeong-Hwan Feb 22, 2024 05:49am
- The Ministry of Health and Welfare has reaffirmed its stance that it will use the health insurance finances saved by the follow-up management measures, including reevaluation of benefit adequacy and reevaluation of the reimbursement standards and conditions, to reimburse drugs that have proven their innovativeness, such as immuno-oncology an
- Company
- Yuhan ‘confirms the safety and efficacy of its allergy drug
- by Son, Hyung-Min Feb 22, 2024 05:49am
- Yuhan Corp announced on Tuesday that the results of the Phase 1a clinical trial of its allergy drug candidate YH35324 were published in the SCI-ranked International Journal of Immunopharmacology. YH35324 is a novel anti-immunoglobulin E (Anti-IgE) class Fc fusion protein drug. Its main mechanism of action improves allergy symptoms by red
- Company
- Samsung Bioepis starts Global P1T for Keytruda biosimilar
- by Kim, Jin-Gu Feb 22, 2024 05:49am
- Samsung Bioepis announced today that it has initiated a global Phase I clinical trial for a biosimilar of Keytruda (pembrolizumab), the world's No. 1 selling drug. The product, which is being developed under the name SB27, is the 11th biosimilar in Samsung Bioepis' pipeline. Samsung Bioepis has recruited 135 volunteer patients with
- Company
- Pfizer’s Zavicefta, sole CRE antibiotic in KOR, gets reimb
- by Son, Hyung-Min Feb 22, 2024 05:49am
- A new antibiotic has been added to the insurance reimbursement listing a year after Zerbaxa. Zavicefta, developed by Pfizer, is the only antibiotic that can be used to treat carbapenem-resistant Enterobacteriaceae (CRE). Experts have stressed the use of this drug only when necessary because there is a growing number of patients with antibi
- Company
- K-made anticancer drugs Leclaza, Rolontis show sales growth
- by Chon, Seung-Hyun Feb 22, 2024 05:49am
- New anticancer drugs developed by Korean pharmaceutical companies are showing a steady growth path in the market. Yuhan’s Leclaza, a lung cancer treatment, surpassed 20 billion won in annual sales, becoming the first domestically developed anticancer drug to achieve this. Hanmi’s Rolontis, a treatment for neutropenia, reached 10 billion won in
- Policy
- ‘Gavreto’ withdrawn from KOR amid reimb rejection
- by Lee, Hye-Kyung Feb 21, 2024 05:45am
- ‘Gavreto Cap. 100mg (pralsetinib),’ previously managed by Roche Korea, will be withdrawn from the Korean market. In February 2023, Roche announced its decision to terminate the global partnership agreement with Blueprint Medicines Corporation (BPM), the drug’s original developer. Furthermore, Gavreto did not clear the reimbursement h
- Company
- K-CAB and Fexuclue, new P-CAB drugs, expand globally
- by Kim, Jin-Gu Feb 21, 2024 05:45am
- New P-CAB class drugs, K-CAB (tegoprazan) and Fexuclue (fexuprazan), for treating gastroesophageal reflux disease are competing for global entries. HK inno.N’s K-CAB has entered 35 countries globally through technology exports or finished product exports. Within a year of its launch, Daewoong Pharmaceutical’s Fexuclue has been introd
- Policy
- President Yoon asks doctors to 'stop collective action'
- by Lee, Jeong-Hwan Feb 21, 2024 05:45am
- President Seok-Yul Yoon said, "Doctors should not hold the lives and health of the people hostage and take collective action, no matter what,” in response to doctors who submitted a collective resignation letter and medical students who decided to take a collective leave of absence in protest to the government’s plan to increase medical
- Company
- Sanofi Korea CEO Kyungeun Bae promoted to head 3 countries
- by Eo, Yun-Ho Feb 21, 2024 05:45am
- Sanofi-Aventis Korea’s Country Manager, Kyungeun Bae(53) is continuing on her prosperous career path. Dailypharm’s coverage found that Bae (Sanofi Korea Country Lead) was recently appointed as the general manager to lead subsidiaries including Korea, New Zealand, and Australia of the Sanofi Group. This is the first time a Korean has bee
